Ad
Thursday, 17 August 2017
FDA approves expanded use of AstraZeneca ovarian cancer drug
(Reuters) - The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment